Clinical Trial

Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment

Study acronym: TOPO-PT
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Intravitreal topotecan exhibits strong anti-inflammatory, anti-proliferative, and anti-fibrotic properties, making it a promising option for preventing and treating proliferative vitreoretinopathy in rhegmatogenous retinal detachment. Preclinical studies have demonstrated its efficacy in proliferative vitreoretinopathy models, where no adverse events have been reported for doses of 5 µg to 30 µg. This prospective, matched cohort study aims to assess the therapeutic efficacy and safety of intravitreal topotecan for preventing and treating proliferative vitreoretinopathy in rhegmatogenous retinal detachment patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-07.
Trial Details
NCT Number NCT06818721
Lead Sponsor Unity Health Toronto
Conditions Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy
Enrollment 394 participants
Start Date 2025-03
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-03-06